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Toyohashi, JapanObjectives The aim of this study was to evaluate the relationship between cholesterol metabolism
and coronary plaque vulnerability.
Background Cholesterol homeostasis, deﬁned as the balance between absorption and synthesis,
inﬂuences the progression of coronary atherosclerosis.
Methods Consecutive stable angina pectoris patients (N ¼ 80) not receiving any lipid-lowering
therapy were divided into 2 groups based on the presence of in vivo thin cap ﬁbroatheroma (TCFA)
in de novo target vessels assessed by the combined use of virtual histology intravascular ultrasound
and optical coherence tomography.
Results Patients with in vivo TCFA (n ¼ 42) showed a higher campesterol-to-lathosterol ratio (3.36
[interquartile range, 2.10 to 4.26] vs. 1.50 [1.20 to 2.50], p < 0.0001). The campesterol-to-lathosterol
ratio, low-density lipoprotein (LDL) cholesterol, and high-sensitivity C-reactive protein (hsCRP) were
positively correlated with the percentage of necrotic core volume (r ¼ 0.520, p < 0.0001; r ¼ 0.520,
p < 0.0001; and r ¼ 0.539, p < 0.0001, respectively) and negatively correlated with thinnest ﬁbrous cap
thickness (r ¼ 0.566, p < 0.0001; r ¼ 0.530, p < 0.0001; and r ¼ 0.358, p ¼ 0.007, respectively) .
The independent predictors of the incidence of TCFA were the campesterol-to-lathosterol ratio (odds
ratio: 3.989, 95% conﬁdence interval: 1.688 to 9.428; p ¼ 0.002), LDL cholesterol (odds ratio: 1.425, 95%
conﬁdence interval: 1.023 to 1.985; p ¼ 0.03), hsCRP (odds ratio: 1.025, 95% conﬁdence interval: 1.003
to 1.047; p ¼ 0.02), and the percentage of necrotic core volume (odds ratio:1.084, 95% conﬁdence
interval: 1.012 to 1.161; p ¼ 0.02).
Conclusions Enhanced absorption and reduced synthesis of cholesterol may be related to coronary
plaque vulnerability. (J Am Coll Cardiol Intv 2013;6:746–55) ª 2013 by the American College of
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VH = Virtual Histology
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747Results of many large-scale trials have documented that
statin therapy is efﬁcacious in lowering lipid risk factors and
subsequent cardiovascular events and mortality (1–3).
However, statins suppress the synthesis of cholesterol con-
siderably less efﬁciently in subjects with low synthesis and
high absorption of cholesterol (4). Consequently, coronary
events have not been reduced by the use of statins in those
patients with high cholesterol absorption (5).
Furthermore, high cholesterol absorption and low
synthesis of cholesterol were associated with more severe
coronary artery disease (CAD) (4) and cardiovascular
mortality (6–8). However, in these studies, CAD was eval-
uated by only coronary artery angiography and the plaque
itself was not observed using coronary imaging modalities.
In addition, severe CAD does not always result in coronary
plaque rupture associated with cardiovascular events.
Therefore, the evaluation of the relationship of cholesterol
metabolism with coronary atherosclerosis and plaque vul-
nerability might play an important role in selecting the
appropriate medication therapy for patients with
dyslipidemia.
Virtual Histology (VH) (Volcano Corporation, Rancho
Cordova, California) intravascular ultrasound (IVUS) uses
spectral analysis of radiofrequency ultrasound backscatter
signals, which allows the identiﬁcation of 4 different types of
atherosclerotic plaque components (9). VH-IVUS is able to
quantify necrotic core; however, it is not able to measure
the thin ﬁbrous cap of an atheroma due to limited resolution
(150 mm). Although optical coherence tomography (OCT)
(LightLab Imaging Inc., Westford, Massachusetts) can
differentiate the thin ﬁbrous cap due to high resolution (10 to
20 mm), the limited penetration (<2 mm) does not allow
quantiﬁcation of plaque components. Thus, neither modality
alone is sufﬁcient for detecting thin cap ﬁbroatheroma
(TCFA) in vivo. However, the combined use of both
modalities might be a feasible approach to more appropriately
identify TCFA (10).
The primary objective of this study was to evaluate the
relationship between the surrogate markers of cholesterol
metabolism to coronary plaque vulnerability evaluated by the
combined use of VH-IVUS and OCT.
Methods
Study population. Patients between 30 and 80 years of age
with clinically stable angina pectoris scheduled for percu-
taneous coronary intervention were enrolled. Inclusion
criteria were the following: 1) patients were not receiving
any lipid-lowering therapy before the enrollment in this
study; 2) a target vessel with >75% de novo luminal nar-
rowing by visual estimation throughout the target segment
with a minimum length of 30 mm; 3) the target vessel for
VH-IVUS and OCT interrogation had mild to moderate
vessel tortuosity and calciﬁcation for safe and accurateexamination; and 4) a left ventricular ejection fraction
>30%. Exclusion criteria were the following: 1) signiﬁcant
stenotic lesions in all coronary vessels; 2) acute coronary
syndrome within the previous 4 weeks; 3) the target vessel
for VH-IVUS and OCT interrogation had lesions with
angiographically detected thrombus; 4) contraindications
to IVUS or OCT examination; 5) lesions with subtotal or
chronic total occlusion that impeded adequate blood
clearance and was not suitable for OCT image acquisition;
6) other concomitant diseases or medical conditions that
could affect patient/procedure outcomes, such as a history
of bleeding diathesis, stroke, or transient ischemic neuro-
logical attacks within the past year and hypersensitivity
to heparin, aspirin, clopidogrel, or x-ray contrast media; 7) a
positive pregnancy test. After diagnostic catheterization,
patients who met eligibility criteria were invited to partici-
pate in this study. All patients were given aspirin (100 mg/d)
and clopidogrel (75 mg/d) for at least 1 week before the
procedure. Informed consent was obtained from all patients.
The study was approved by the
institutional ethics committee.
Laboratory procedures. Fasting
blood samples collected before
angiography were kept frozen at
80C between the day of blood
drawing and the day of analysis.
Plasma total cholesterol, triglyc-
erides, and high-density lipopro-
tein cholesterol concentrations were
measuredusing standard enzymatic
methods (11,12). Low-density-
lipoprotein (LDL) cholesterol
concentrations were calculated
according to the Friedewald for-
mula (13). Campesterol, sitos-
terol, and lathosterolwere quantiﬁed in plasma using a recently
published gas chromatography and mass spectrometry-based
method (14,15).
IVUS procedure. During the procedure, heparin was given as
a bolus of 150 U/kg with additional boluses to 2,000 U/h.
All IVUS imaging was performed after administration of
200 mg nitroglycerin. For the IVUS procedure, a 20-MHz,
3.2-F, phased-array IVUS catheter (Eagle Eye, Volcano
Therapeutics, Rancho Cordova, California) was used. After
placing the IVUS catheter at a point at least 30 mm distal
from the coronary ostium as well as distal to the target
lesion, the catheter was pulled back to the coronary ostium
using a motorized pull-back system at 0.5 cm/s. During
pull back, gray-scale IVUS was recorded and raw radio-
frequency data were captured at the top of the R wave for
reconstruction of the color-coded map by a VH-IVUS data
recorder (Volcano Therapeutics). The gray-scale IVUS im-
aging and captured radiofrequency data were written to
a CD-R and DVD-R, respectively.
Figure 1. A Case With Deﬁnite Thin Cap Fibroatheroma
(A) Coronary angiography demonstrated an intermediate lesion (arrow). (B)
The corresponding Virtual Histology intravascular ultrasound (VH-IVUS) image
presents VH-IVUS–derived thin cap ﬁbroatheroma (TCFA). The percentage of
necrotic core area was 54% without evidence of a ﬁbrous cap and the
percentage of plaque plus media cross-sectional area was 68%. (C) The cor-
responding optical coherence tomography (OCT) image presents OCT-derived
TCFA. The ﬁbrous cap thickness overlying a lipid-rich plaque at the thinnest
part was 50 mm (arrow).
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748IVUS analysis and deﬁnition of VH-IVUS–derived TCFA. Mea-
surements were made of the target vessel, which was deﬁned
as the segment from distal to the target lesion to the coro-
nary ostium, evaluating a minimal length of 30 mm. Manual
contour detection of both the lumen and the media-
adventitia interface was performed by 2 experienced analysts
who were blinded to baseline clinical and angiographic
lesion characteristics. Intraobserver and interobserver anal-
yses of random samples of 45 patients were performed by the
2 experienced analysts. The ﬁrst analyst repeated a blind
analysis at least 2 weeks apart for intraobserver analysis.
Intraobserver and interobserver differences in measurements
of external elastic membrane volume were 3.6  2.2%
and 4.2  2.3%, respectively. External elastic membrane
volume and lumen volume were calculated, and the differ-
ence between the 2 values was deﬁned as plaque plus media
volume. Atherosclerotic coronary plaques between the
lumen and media-adventitia contours were characterized
automatically with the use of custom-built software
(IVUSLab software, Volcano Therapeutics) which uses
classiﬁcation trees based on mathematical autoregressive
spectral analysis of IVUS backscattered data, as described
previously (9,16). Fibrous areas were marked in green, ﬁbro-
fatty in yellow, dense calcium in white, and necrotic core in
red on the VH-IVUS image. The absolute value of each
plaque component volume was also calculated automatically
by the software. The relative value was deﬁned as the volume
of each plaque component divided by the total amount of
plaque volume.
VH-IVUS–derived TCFA was deﬁned as lesions ful-
ﬁlling the following criteria in at least 3 consecutive cross-
sectional images by 2 experienced, independent observers:
1) percentage necrotic core area >20% without evidence of
ﬁbrous cap and 2) percentage of plaque plus media cross-
sectional area 40%. The cutoff value was selected based
on previous pathological and in vivo VH-IVUS ﬁndings
(17–19).
OCT procedure. The OCT image acquisition was performed
with a commercially available system for intracoronary
imaging (LightLab Imaging, Inc., St. Jude, Minneapolis,
Minnesota). The Image Wire (LightLab Imaging, Inc.) was
positioned at a point at least 30 mm distal to the coronary
ostium as well as distal to the target lesion with an over-the-
wire type occlusion balloon catheter (Helios, LightLab
Imaging Inc.). To clear blood from the imaging site, the
occlusion balloon was inﬂated from 0.5 to 0.7 atm with
a customized inﬂation device, and lactated Ringer’s solution
was infused in the coronary artery from the distal tip of the
occlusion balloon at the rate of 0.5 to 0.9 ml/s. Motorized
pull-back OCT imaging was performed at a rate of 1.0 mm/
s, and OCT data were recorded on a CD-ROM for ofﬂine
analysis. If the length from initial wire position to the
balloon site was >50 mm, the OCT image acquisition was
Table 1. Baseline Clinical Characteristics and Laboratory Data
Variable Deﬁnite TCFA (þ) Deﬁnite TCFA () p Value
Patients, no. 42 38
Age, yrs 71.0 (66.0–77.0) 67.0 (60.0–73.3) 0.27
Body mass index, kg/m2 22.7 (21.1–26.6) 23.5 (21.7–26.8) 0.4
Male, no. (%) 32 (76) 31 (82) 0.6
Metabolic syndrome, no. (%) 14 (33) 15 (39) 0.64
Diabetes, no. (% 12 (29) 12 (32) 0.3
Hypertension, no. (%) 26 (62) 28 (74) 0.49
Hyperlipidemia, no. (%) 16 (38) 15 (39) >0.99
Smoker, no. (%) 7 (17) 7 (18) >0.99
Total cholesterol, mg/dl 213.5 (184.0–248.0) 193 (171.0–224.5) 0.03
Triglyceride, mg/dl 130.0 (90.0–180.2) 118.4 (81.8–164.3) 0.46
LDL cholesterol, mg/dl 130.1 (113.2–155.0) 112.2 (90.0–122.3) 0.002
HDL cholesterol, mg/dl 47.5 (43.0–61.4) 54.0 (45.8–60.3) 0.39
Lathosterol, mg/100 mg total cholesterol 60.1 (50.0–73.0) 91.3 (57.1–142.8) 0.009
Campesterol, mg/100 mg total cholesterol 195.8 (154.1–248.6) 137.6 (114.2–181.1) 0.004
Sitosterol, mg/100 mg total cholesterol 146.7 (118.1–174.4) 115.2 (90.9–132.7) 0.002
Ratio of campesterol to lathosterol 3.36 (2.10–4.26) 1.50 (1.20–2.05) <0.0001
hsCRP, ng/ml 705.0 (452.5–1,185.0) 441 (340.0–670.2) 0.02
Values are median (interquartile range) unless otherwise speciﬁed.
HDL ¼ high-density lipoprotein; hsCRP ¼ high-sensitivity C-reactive protein; LDL ¼ low-density lipoprotein; TCFA ¼ thin cap ﬁbroatheroma.
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749performed again at a proximal part of the target vessel. The 2
OCT-imaged segments were overlapped by using a side
branch as a landmark.
OCT analysis and deﬁnition of OCT-derived TCFA. OCT-
derived TCFA was deﬁned as lesions fulﬁlling the following
criteria in at least 3 consecutive cross-sectional images by 2
experienced, independent observers: 1) the presence of lipid-
rich plaque deﬁned as a signal-poor region with unclear
borders and 2) the presence of a thin ﬁbrous cap (<65 mm)
overlying a lipid-rich plaque (20). The thinnest part of theTable 2. Gray-scale and Virtual Histology Intravascular Ultrasound Data
Variable Deﬁnite TCFA (þ)
Analyzed vessel, no. (%) 42
LAD 15 (36)
LCX 12 (28)
RCA 15 (36)
Length of image segment, mm 47.0 (35.7–71.4)
External elastic membrane volume, mm3 719.0 (587.5–836.6)
Lumen volume, mm3 273.0 (243.5–345.0)
Plaque plus media volume, mm3 422.1 (338.9–473.7)
Fibrous tissue volume, mm3 142.3 (98.6–184.2)
Fibro-fatty volume, mm3 28.2 (16.5–34.1)
Necrotic core volume, mm3 49.5 (30.0–78.6)
Dense calcium volume, mm3 22.0 (13.3–42.1)
Fibrous tissue, % 56.3 (48.8–61.6)
Fibro-fatty, % 10.8 (9.1–16.5)
Necrotic core, % 21.3 (15.1–27.3)
Dense calcium, % 9.7 (6.9–19.9)
Values are median (interquartile range) unless otherwise speciﬁed.
LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex; RCA ¼ right coronary artery; TCFA ¼ tﬁbrous cap was measured 3 times, and its average was
deﬁned as OCT ﬁbrous cap thickness (21,22). If the patient
had >1 OCT-derived TCFA, each ﬁbrous cap was
measured and the value of the thinnest one was used for
analysis. Intraobserver and interobserver analyses of random
samples from 45 patients were performed by the 2 experi-
enced analysts. The ﬁrst analyst repeated a blind analysis at
least 2 weeks apart for intraobserver analysis. Intraobserver
and interobserver differences in measurements of the ﬁbrous
cap thickness were 4.5  1.2% and 4.3  1.7%, respectively.Deﬁnite TCFA (–) p Value
38
18 (47)
8 (21)
12 (31)
41.1 (32.6–58.0) 0.3
701.1 (609.2–787.2) 0.2
289.0 (223.0–346.0) 0.2
402.2 (300.9–451.8) 0.3
148.4 (106.8–196.5) 0.2
36.5 (18.3–50.0) 0.1
30.5 (20.7–46.9) 0.1
17.1 (6.9–29.2) 0.4
62.6 (51.1–70.8) 0.1
13.6 (9.6–17.2) 0.2
16.6 (9.0–19.2) 0.01
6.7 (3.7–14.2) 0.2
hin cap ﬁbroatheroma.
Figure 2. Correlation Between Relative Value of Each Plaque Component Volume and Ratio of Campesterol to Lathosterol
The percentage of ﬁbrous tissue and ﬁbro-fatty volumes was negatively correlated with the ratio of campesterol to lathosterol (p ¼ 0.007 [A]) and (p ¼ 0.002 [B]).
The percentage of necrotic core and dense calcium volumes were positively correlated (p < 0.0001 [C]) and (p ¼ 0.03 [D]).
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750Those agreements for the detection of OCT-derived TCFA
were within an acceptable range (intraobserver: kappa ¼
0.74, interobserver; kappa ¼ 0.77).
Deﬁnition of deﬁnite TCFA. Both VH-IVUS and OCT
images of identical lesions were compared using the location of
side branches or calciﬁcation as landmarks (10). Plaque that
met the criteria of both VH-derived TCFA and
OCT-derived TCFA was deﬁned as deﬁnite TCFA. A
representative case of deﬁnite TCFA is shown in Figure 1.
Intraobserver and interobserver analyses of random samples
from45 patients were performed by the 2 experienced analysts.
The ﬁrst analyst repeated a blind analysis at least 2 weeks apart
for intraobserver analysis. Those agreements for the detection
of deﬁnite TCFA were within an acceptable range (intra-
observer: kappa ¼ 0.82, interobserver; kappa ¼ 0.86).
Statistical analysis. Continuous variables are expressed as a
median (interquartile range). Categorical data are expressed as
the number or frequency of occurrences. Comparison of
continuous variables was performed using a nonparametric
Mann-Whitney U test. The chi-square or Fisher’s exact test
for sparse data was used for comparing the frequency ofoccurrence. Linear regression analysis was performed to
investigate the correlation of laboratory data with relative value
of each plaque component evaluated by VH-IVUS
and thinnest ﬁbrous cap thickness evaluated by OCT. A
multivariate logistic regression analysis was used to determine
the signiﬁcant factors indicating the presence of TCFA. All
clinical features along with gray-scale and VH-IVUS results
were evaluated in a univariate analysis. The factors were
entered intomultivariablemodels if their univariate p valuewas
<0.1. To assess the intraobserver and interobserver variabil-
ities, the results were compared with kappa test of concordance
to the categorical data, and aBland-Altmanplotwas fulﬁlled to
continuous data. SPSS version 15.0 (SPSS, Inc., Chicago,
Illinois)was used for data analysis.Aprobability value of<0.05
was considered to indicate statistical signiﬁcance.
Results
Patient characteristics, laboratory data, and procedural
results. From September 2009 to December 2010, 84
patients (84 vessels) met all inclusion and exclusion criteria,
Figure 3. Correlation Between Relative Value of Each Plaque Component Volume and Low-Density Lipoprotein Cholesterol Level
The percentage of ﬁbrous tissue and ﬁbro-fatty volume were negatively correlated with low-density lipoprotein (LDL) cholesterol level (p ¼ 0.0002 [A]) and (p ¼ 0.02
[B]). The percentage of necrotic core and dense calcium volumes were positively correlated (p < 0.0001 [C]) and (p ¼ 0.006 [D]).
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751and informed consent was obtained. Of those patients,
4 vessels in 4 patients were not included in this study due
to poor image quality for VH IVUS or OCT analysis. A
total of 80 patients without any lipid-lowering therapies
were enrolled. The clinical characteristics and laboratory
data are summarized in Table 1. At least 1 deﬁnite TCFA
was observed in 42 (53%) patients (42 vessels). There was
no variation in patient characteristics between the 2 groups.
LDL cholesterol level, campesterol-to-cholesterol ratio,
sitosterol-to-cholesterol ratio, campesterol-to-lathosterol
ratio, and high-sensitivity C-reactive protein (hsCRP) level
were signiﬁcantly higher in the deﬁnite TCFA group;
however, the lathosterol-to-cholesterol ratio was signiﬁ-
cantly lower than the nondeﬁnite TCFA group. There was
no periprocedural myocardial infarction in both groups.
Gray-scale and VH-IVUS data. Table 2 shows quantitative
gray-scale and VH-IVUS measurements. The length of the
imaged segment was 43.0 mm (range, 33.2 to 68.7 mm). The
results of gray-scale IVUS measurements show no difference
between the 2 groups. In VH-IVUS measurements, relativevalues of necrotic core were signiﬁcantly larger in the deﬁnite
TCFA group.
The correlation relative value of each plaque component
volume with laboratory data is summarized in Figures 2
through 4. The percentage of ﬁbrous tissue and ﬁbro-fatty
volumes was signiﬁcantly negatively correlated with the cam-
pesterol-to-lathosterol ratio, LDLcholesterol level, and hsCRP
level, but percentage of necrotic core volume was signiﬁcantly
positively correlated. There was a signiﬁcantly positive corre-
lation between the percentage of dense calcium volume with
LDL-cholesterol and the campesterol-to-lathosterol ratio.
OCT data. In the deﬁnite TCFA group, 24 patients had only
1 TCFA, 12 had 2 TCFAs, and 6 had >3 TCFAs in the
target vessel. Alternatively, 32 patients had TCFAs and 6
had ﬁbrotic plaques in the nondeﬁnite TCFA group. The
correlation between OCT ﬁbrous cap thickness with labo-
ratory data is summarized in Figure 5. There was signiﬁcant
negative correlation between thinnest ﬁbrous cap thickness
with the campesterol-to-lathosterol ratio, LDL cholesterol
level, and hsCRP level.
Figure 4. Correlation Between Relative Value of Each Plaque Component Volume and High-Sensitivity C-Reactive Protein Level
The percentage of ﬁbrous tissue and ﬁbro-fatty volumes were negatively correlated with high-sensitivity C-reactive protein (hsCRP) level (p ¼ 0.004 [A]) and (p ¼ 0.006
[B]). The percentage of necrotic core was positively correlated (p < 0.0001 [C]). (D) There was no signiﬁcant correlation between the percentage of dense calcium
volume and hsCRP level.
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752Independent predictors of the incidence of deﬁnite
TCFA. The independent predictors of the incidence of
deﬁnite TCFA were the campesterol-to-lathosterol ratio,
LDL cholesterol (per 10 mg/dl), hsCRP (per 10 ng/ml), and
the percentage of necrotic core volume (Table 3).Discussion
The novel ﬁndings of this study were the following: 1)
subjects with at least 1 deﬁnite TCFA in their coronary
arteries with signiﬁcant stenosis showed a higher ratio of
cholesterol absorption to cholesterol synthesis; 2) a higher
ratio of cholesterol absorption to cholesterol synthesis was
signiﬁcantly correlated with a higher percentage of necrotic
core volume and lower ﬁbrous cap thickness; 3) independent
predictors of the incidence of deﬁnite TCFA were not only
LDL cholesterol and hsCRP levels but also ratio of cho-
lesterol absorption to cholesterol synthesis.Cholesterol metabolism and vulnerable plaque. It is well-
known that higher inﬂammatory status and LDL cholesterol
level are the major risk factors for vulnerable plaque (23,24).
Although many previous studies assessed the relationship
between cholesterol homeostasis and cardiovascular disease
risk, the conclusions have not been clearly established.
Wilund et al. (25) reported no signiﬁcant association
between the concentration of cholesterol absorption makers
with the incidence of family history of CAD and coronary
artery calcium score. In addition, the EPIC-Norfolk study
(26) and the LASA study (27) reported that increased
concentration of cholesterol absorption makers were asso-
ciated with decreased CAD risk. It is speculated that
differences in baseline characteristics such as age, plasma
lipoprotein proﬁle, and medication status including lipid-
lowering therapy, which potentially affect the stage of
disease and thus the magnitude or direction of the associa-
tions observed, account for the different results in previously
published studies. On the other hand, some previous studies
Figure 5. Correlation Between Thinnest Fibrous Cap Thickness Assessed
by Optical Coherence Tomography and Laboratory Data
The ratio of campesterol to lathosterol, LDL cholesterol level, and hsCRP level
were negatively correlated with ﬁbrous cap thickness as shown: p < 0.0001
(A), p < 0.0001 (B), and p ¼ 0.007 (C). OCT ¼ optical coherence tomography;
other abbreviations as in Figures 3 and 4.
Table 3. Independent Predictors of the Incidence of TCFA
Label
Odds Ratio
(95% Conﬁdence Interval) p Value
Ratio of campesterol to lathosterol 3.989 (1.688–9.428) 0.002
LDL cholesterol, per 10 mg/dl 1.425 (1.023–1.985) 0.03
hsCRP, per 10 ng/ml 1.025 (1.003–1.047) 0.02
Necrotic core, % 1.084 (1.012–1.161) 0.02
Abbreviations as in Table 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 7 , 2 0 1 3 Nasu et al.
J U L Y 2 0 1 3 : 7 4 6 – 5 5 Cholesterol Metabolism and Coronary Plaque
753have reported that enhanced absorption and reduced
synthesis of cholesterol were signiﬁcantly associated with
CAD severity in patients undergoing coronary angiography
(4,15,28). However, it must be noted that subjects were notclassiﬁed on the plaque morphology in their coronary
arteries.
From the results of this study, the ratio of cholesterol
absorption to cholesterol synthesis was higher in the deﬁnite
TCFA group. In the VH IVUS analysis, the percentage of
necrotic core volume measured by VH-IVUS was signiﬁ-
cantly positively correlated with the ratio of cholesterol
absorption to cholesterol synthesis. On the other hand,
OCT ﬁbrous-cap thickness was signiﬁcantly negatively
correlated with this ratio. In addition, higher LDL
cholesterol, higher hsCRP, and a higher ratio of cholesterol
absorption to cholesterol synthesis were independent
predictors of the incidence of deﬁnite TCFA in the target
vessel. Thus, higher cholesterol absorption and lower
synthesis may provide important information to predict the
progression of atherosclerosis and the presence of TCFA in
a coronary artery.
Role of plant sterols in the development of coronary
atheroma. The mechanism of associations between cho-
lesterol metabolism and coronary atherosclerosis are not
fully understood. It is well-known that diet supplementa-
tion with plant sterol ester is associated with a LDL
cholesterol–lowering effect (29,30). Thus, the lifestyle of
study patients, particularly dietary intervention with plant
sterols, might have some effects on LDL cholesterol level.
On the other hand, the serum plant sterol levels were
signiﬁcant indicators of cholesterol absorption and synthesis
(11). In a previous study, the higher the ratio of dietary
absorption markers to serum cholesterol, the higher the
ratio was also in the carotid artery wall (31). However, high
plant sterol intake did not result in serum high plant sterol
concentrations (32). These results may show that high plant
sterol concentrations in animal cell membranes offer
a possible danger to the well-being of the cell owner,
limiting intestinal absorption of plant sterol (31). This
speculation may be supported by the results of a previous
study in which subjects with a marked increase in choles-
terol absorption by mutation of ABCG5/8 genes in intes-
tinal enterocytes and the liver had severe coronary artery
atherosclerosis (33). Thus, the serum surrogate marker
levels of cholesterol metabolism may reﬂect cholesterol
absorption and synthesis capacities. Therefore, from the
results of this study, the high cholesterol absorption status
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754may be one of the risks of accelerating atherosclerosis, and
baseline cholesterol metabolism may predict the risk of
future cardiovascular events. However, further studies are
needed not only to better understand the signiﬁcance of
serum plant sterols in the development of coronary
atherosclerosis but also to select appropriate lipid-lowering
therapy.
Study limitations. This study is based on a small number of
patients, raising the possibility of selection bias. Study of
larger patient populations from multiple centers is warranted
to conﬁrm these data. Due to the fact that acute coronary
syndrome patients at high risk for OCT or VH-IVUS
procedures were excluded from this study, we could not
achieve any conclusions about the general prevalence of
TCFA. TCFA could appear in other nontarget vessels in
the nondeﬁnite TCFA group because only the target vessel
was analyzed by OCT and VH-IVUS in this study. A
combination of both OCT and VH-IVUS was used to
identify TCFA because combined use of these modalities
made up for the limitation of each modality and improved
the sensitivity and speciﬁcity of detecting in vivo TCFA
(10). However, we did not directly compare these ﬁndings
with pathology due to the in vivo study design. Time-
domain OCT technology requires an occlusion balloon to
clear blood from the imaging site, and the pull-back speed
of this system is relatively lower (1 mm/s) compared with
that of the newest system (20 mm/s). We could observe only
limited vessel areas because the procedures of both modal-
ities have several limitations for imaging certain lesions,
such as tortuous, calciﬁed, and other complex lesions.
Patients receiving any lipid-lowering therapies were not
enrolled as any lipid-lowering therapy might change
surrogate makers of cholesterol absorption and synthesis.
However, we cannot exclude the inﬂuence of other medi-
cations for other risk factors such as hypertension and dia-
betes mellitus. Following the design of this study protocol,
percutaneous coronary intervention was performed without
the loading of lipid-lowering therapy. Although patients
with unstable lesions (which included angiographically
detected thrombus) were excluded and there was no peri-
procedural myocardial infarction in this study, the study
protocol might not entirely remove the risk of periproce-
dural myocardial infarction. Campesterol and sitosterol,
used as the absorption markers, might be inﬂuenced by
dietary plant sterols. However, the results of these markers
were in agreement with the data using cholestanol, which
was not inﬂuenced by dietary plant sterol in previous studies
(15). Finally, although a higher cholesterol absorption–to–
cholesterol synthesis ratio was signiﬁcantly correlated with
a higher percentage of necrotic core volume and lower
ﬁbrous cap thickness on linear regression analysis, the low
coefﬁcient of determination might be affected by those
various factors that were associated with the progression of
atherosclerosis.Conclusions
Not only LDL cholesterol level and inﬂammatory status, but
also enhanced absorption and reduced synthesis of choles-
terol may be related to plaque vulnerability in the coronary
artery with signiﬁcant stenosis. However, further studies
are necessary to evaluate the role of plant sterols on the
progression of atherosclerosis.Acknowledgments
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